Sugimoto Y - Search Results

1

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y. Noguchi K, et al. Among authors: sugimoto y. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. Cancer Sci. 2009. PMID: 19493273 Free PMC article.

2

Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.

Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Sugimoto Y, et al. Cancer Sci. 2005 Aug;96(8):457-65. doi: 10.1111/j.1349-7006.2005.00081.x. Cancer Sci. 2005. PMID: 16108826 Free PMC article. Review.

3

Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.

Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Yanase K, et al. Among authors: sugimoto y. Cancer Lett. 2006 Mar 8;234(1):73-80. doi: 10.1016/j.canlet.2005.04.039. Epub 2005 Nov 21. Cancer Lett. 2006. PMID: 16303243 Review.

4

A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein.

Mutoh K, Mitsuhashi J, Kimura Y, Tsukahara S, Ishikawa E, Sai K, Ozawa S, Sawada J, Ueda K, Katayama K, Sugimoto Y. Mutoh K, et al. Among authors: sugimoto y. Mol Cancer Ther. 2006 Apr;5(4):877-84. doi: 10.1158/1535-7163.MCT-05-0240. Mol Cancer Ther. 2006. PMID: 16648557

5

Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.

Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Mutoh K, et al. Among authors: sugimoto y. Cancer Sci. 2006 Nov;97(11):1198-204. doi: 10.1111/j.1349-7006.2006.00300.x. Epub 2006 Aug 22. Cancer Sci. 2006. PMID: 16925584 Free PMC article.

6

Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y. Katayama K, et al. Among authors: sugimoto y. Cancer Chemother Pharmacol. 2007 Nov;60(6):789-97. doi: 10.1007/s00280-007-0426-7. Epub 2007 Mar 8. Cancer Chemother Pharmacol. 2007. PMID: 17345086

7

Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein.

Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Katayama K, et al. Among authors: sugimoto y. Mol Cancer Ther. 2007 Jul;6(7):2092-102. doi: 10.1158/1535-7163.MCT-07-0148. Mol Cancer Ther. 2007. PMID: 17620438

8

Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.

Takahashi S, Aiba K, Ito Y, Hatake K, Nakane M, Kobayashi T, Minowa S, Shibata H, Mitsuhashi J, Tsukahara S, Ishikawa E, Suzuki R, Tsuruo T, Sugimoto Y. Takahashi S, et al. Among authors: sugimoto y. Cancer Sci. 2007 Oct;98(10):1609-16. doi: 10.1111/j.1349-7006.2007.00571.x. Epub 2007 Aug 7. Cancer Sci. 2007. PMID: 17683514 Free PMC article.

9

Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.

Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Noguchi K, et al. Among authors: sugimoto y. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. doi: 10.1016/j.addr.2008.07.003. Epub 2008 Dec 3. Adv Drug Deliv Rev. 2009. PMID: 19111841 Review.

10

Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.

Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y. Katayama K, et al. Among authors: sugimoto y. Anticancer Res. 2009 Apr;29(4):1059-65. Anticancer Res. 2009. PMID: 19414346 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,687 results

Search Page

Filters